Sleep Deprivation Induced Fat Accumulation in the Visceral White Adipose Tissue by Suppressing SIRT1/FOXO1/ATGL Pathway Activation

Overview

Journal J Physiol Biochem

Specialties Biochemistry
Physiology

Date 2024 Jun 10

PMID 38856814

Authors

Wei Wang

Kun Liu

Huan Xu

Chongchong Zhang

Yifan Zhang

Mengnan Ding

Chen Xing

Xin Huang

Qing Wen

Chunfeng Lu

Lun Song

Affiliations

Soon will be listed here.

Abstract

Sleep is critical for maintaining overall health. Insufficient sleep duration and poor sleep quality are associated with various physical and mental health risks and chronic diseases. To date, plenty of epidemiological research has shown that sleep disorders are associated with the risk of obesity, which is usually featured by the expansion of adipose tissue. However, the underlying mechanism of increased fat accumulation upon sleep disorders remains unclear. Here we demonstrated that sleep deprivation (SD) caused triglycerides (TG) accumulation in the visceral white adipose tissue (vWAT), accompanied by a remarkable decrease in the expression of adipose triglyceride lipase (ATGL) and other two rate-limiting lipolytic enzymes. Due to the key role of ATGL in initiating and controlling lipolysis, we focused on investigating the signaling pathway leading to attenuated ATGL expression in vWAT upon SD in the following study. We observed that ATGL downregulation resulted from the suppression of ATGL transcription, which was mediated by the reduction of the transcriptional factor FOXO1 and its upstream regulator SIRT1 expression in vWAT after SD. Furthermore, impairment of SIRT1/FOXO1/ATGL pathway activation and lipolysis induced by SIRT1 inhibitor EX527 in the 3 T3-L1 adipocytes were efficiently rescued by the SIRT1 activator resveratrol. Most notably, resveratrol administration in SD mice revitalized the SIRT1/FOXO1/ATGL pathway activation and lipid mobilization in vWAT. These findings suggest that targeting the SIRT1/FOXO1/ATGL pathway may offer a promising strategy to mitigate fat accumulation in vWAT and reduce obesity risk associated with sleep disorders.

References

Aguirre L, Fernandez-Quintela A, Arias N, Portillo M . Resveratrol: anti-obesity mechanisms of action. Molecules. 2014; 19(11):18632-55. PMC: 6271102. DOI: 10.3390/molecules191118632. View

Arias N, Teresa Macarulla M, Aguirre L, Milton I, Portillo M . The combination of resveratrol and quercetin enhances the individual effects of these molecules on triacylglycerol metabolism in white adipose tissue. Eur J Nutr. 2015; 55(1):341-8. DOI: 10.1007/s00394-015-0854-9. View

Carbone L . Pain management standards in the eighth edition of the Guide for the Care and Use of Laboratory Animals. J Am Assoc Lab Anim Sci. 2012; 51(3):322-8. PMC: 3358980. View

Cedernaes J, Schonke M, Westholm J, Mi J, Chibalin A, Voisin S . Acute sleep loss results in tissue-specific alterations in genome-wide DNA methylation state and metabolic fuel utilization in humans. Sci Adv. 2018; 4(8):eaar8590. PMC: 6105229. DOI: 10.1126/sciadv.aar8590. View

Chaix A, Lin T, Le H, Chang M, Panda S . Time-Restricted Feeding Prevents Obesity and Metabolic Syndrome in Mice Lacking a Circadian Clock. Cell Metab. 2018; 29(2):303-319.e4. PMC: 7751278. DOI: 10.1016/j.cmet.2018.08.004. View

Chakrabarti P, English T, Karki S, Qiang L, Tao R, Kim J . SIRT1 controls lipolysis in adipocytes via FOXO1-mediated expression of ATGL. J Lipid Res. 2011; 52(9):1693-701. PMC: 3151689. DOI: 10.1194/jlr.M014647. View

Chang H, Guarente L . SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab. 2014; 25(3):138-45. PMC: 3943707. DOI: 10.1016/j.tem.2013.12.001. View

Chaput J, McHill A, Cox R, Broussard J, Dutil C, da Costa B . The role of insufficient sleep and circadian misalignment in obesity. Nat Rev Endocrinol. 2022; 19(2):82-97. PMC: 9590398. DOI: 10.1038/s41574-022-00747-7. View

Cohen P, Kajimura S . The cellular and functional complexity of thermogenic fat. Nat Rev Mol Cell Biol. 2021; 22(6):393-409. PMC: 8159882. DOI: 10.1038/s41580-021-00350-0. View

10.

Daniels S . Sleep and obesity. J Pediatr. 2018; 203:3. DOI: 10.1016/j.jpeds.2018.10.014. View

11.

Delpino F, Figueiredo L, Caputo E, Mintem G, Gigante D . What is the effect of resveratrol on obesity? A systematic review and meta-analysis. Clin Nutr ESPEN. 2021; 41:59-67. DOI: 10.1016/j.clnesp.2020.11.025. View

12.

Gazdzinska A, Jagielski P, Turczynska M, Dziuda L, Gazdzinski S . Assessment of Risk Factors for Development of Overweight and Obesity among Soldiers of Polish Armed Forces Participating in the National Health Programme 2016-2020. Int J Environ Res Public Health. 2022; 19(5). PMC: 8909950. DOI: 10.3390/ijerph19053069. View

13.

Hillsley A, Chin V, Li A, McLachlan C . Resveratrol for Weight Loss in Obesity: An Assessment of Randomized Control Trial Designs in ClinicalTrials.gov. Nutrients. 2022; 14(7). PMC: 9002514. DOI: 10.3390/nu14071424. View

14.

Kim S, Jin Y, Choi Y, Park T . Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol. 2011; 81(11):1343-51. DOI: 10.1016/j.bcp.2011.03.012. View

15.

Koenen M, Hill M, Cohen P, Sowers J . Obesity, Adipose Tissue and Vascular Dysfunction. Circ Res. 2021; 128(7):951-968. PMC: 8026272. DOI: 10.1161/CIRCRESAHA.121.318093. View

16.

Liew S, Aung T . Sleep deprivation and its association with diseases- a review. Sleep Med. 2020; 77:192-204. DOI: 10.1016/j.sleep.2020.07.048. View

17.

Majeed Y, Halabi N, Madani A, Engelke R, Bhagwat A, Abdesselem H . SIRT1 promotes lipid metabolism and mitochondrial biogenesis in adipocytes and coordinates adipogenesis by targeting key enzymatic pathways. Sci Rep. 2021; 11(1):8177. PMC: 8046990. DOI: 10.1038/s41598-021-87759-x. View

18.

Malin S, Remchak M, Smith A, Ragland T, Heiston E, Cheema U . Early chronotype with metabolic syndrome favours resting and exercise fat oxidation in relation to insulin-stimulated non-oxidative glucose disposal. Exp Physiol. 2022; 107(11):1255-1264. PMC: 9633545. DOI: 10.1113/EP090613. View

19.

Mongioi L, La Vignera S, Cannarella R, Cimino L, Compagnone M, Condorelli R . The Role of Resveratrol Administration in Human Obesity. Int J Mol Sci. 2021; 22(9). PMC: 8122246. DOI: 10.3390/ijms22094362. View

20.

Nedeltcheva A, Scheer F . Metabolic effects of sleep disruption, links to obesity and diabetes. Curr Opin Endocrinol Diabetes Obes. 2014; 21(4):293-8. PMC: 4370346. DOI: 10.1097/MED.0000000000000082. View